Tempest Therapeutics, Inc.

Tempest Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics targeting oncology indications. The company's lead product candidate, Amezalpat, is an oral selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR-α) in clinical development for first-line unresectable or metastatic hepatocellular carcinoma. A second clinical-stage candidate, TPST-1495, is a dual antagonist of prostaglandin E2 receptors EP2 and EP4 being evaluated across multiple cancer types. The company is advancing Amezalpat through a global first-line randomized study in collaboration with F. Hoffmann-La Roche Ltd.

As a clinical-stage entity, Tempest has not generated product revenues. The company operates with a lean organizational structure of 24 full-time employees and is headquartered in Brisbane, California. The company is incorporated in Delaware and trades on the Nasdaq.